Summit Homes, a Berkshire Hathaway subsidiary through Clayton Properties Group, presented St. Jude Children’s Research Hospital representatives a check for $718,000 following the sale of the builder’s 2017 St. Jude Dream Home Showplace.
Summit Homes, the largest new home builder in Kansas City, built the 2017 St. Jude Dream Home Showplace as an extension of the St. Jude Dream Home® Giveaway Program, to support children battling cancer and other catastrophic diseases. The builder pledged 100% of proceeds from the sale of the home to as a donation for the research hospital.
To view the multimedia release go to:
https://www.multivu.com/players/English/8011654-clayton-summit-homes-st-jude-dream-home-2017/
St. Jude Children’s Research Hospital®, uno de los principales centros de investigación y tratamiento del cáncer pediátrico se unió a Univision Radio, la mayor difusora de radio Hispana en los Estados Unidos, para realizar su evento radial anual Promesa y Esperanza®. Los radioyentes alrededor del país sintonizaron su estación favorita de Univision Radio el 7 y 8 de febrero y recaudaron más de $5.3 millones en efectivo y promesas monetarias. Los fondos recaudados ayudarán a cubrir los gastos de investigación y tratamiento del cáncer pediátrico y otras enfermedades terminales en los Estados Unidos, Puerto Rico y alrededor del mundo.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58260-st-jude-childrens-research-hospital-univision-radio-promesa-y-esperanza
The St. Jude Promesa y Esperanza® (Promise and Hope), an initiative by St. Jude Children’s Research Hospital® and Univision Radio, the leading radio network serving Hispanic America, partner to increase awareness for national fundraiser against childhood cancer. As part of this partnership, Univision Radio will broadcast special programming on February 10 and 11 asking listeners to become Angeles de Esperanza (Angels of Hope) by making a donation of $20 per month, to find cures and save children.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65476-univision-radio-st-jude-children-s-research-hospital-national-fundraiser
Lancôme is unveiling Genes Day on October 22, a one day fundraiser in support of St. Jude Children’s Research Hospital.
In celebration of the beauty of scientific research, Lancôme will donate $7 from each bottle of their latest skin care breakthrough, Génifique Youth Activating Concentrate, sold that day to St. Jude Children’s Research Hospital to support the research and treatment at St. Jude.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lancome/46646/
EN ESTA TEMPORADA FESTIVA, ST. JUDE CHILDREN’S RESEARCH HOSPITAL TE INVITA A PARTICIPAR EN SU CAMPAÑA THANKS AND GIVING. ® UN PROGRAMA ANUAL QUE BUSCA CREAR CONCIENCIA Y RECAUDAR FONDOS PARA COMBATIR EL CÁNCER INFANTIL.
On October 21st, 2011, Lancôme invites customers to experience the “Beauty of Giving” by celebrating Genes Day, a one-day national event Lancôme began in 2010 to support St. Jude Children’s Research Hospital, one of the world’s premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases. On this day, Lancôme will donate $7 from the sale of every bottle of Génifique Youth Activating Concentrate to St. Jude. (This is in addition to special promotions and events nationwide surrounding Genes Day throughout the month of October.)
To view Multimedia News Release, go to http://www.multivu.com/mnr/52300-lancome-genes-day-2011-st-jude-julia-roberts-genifique-beauty-of-giving
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
